Alan John Connor

Learn More
BACKGROUND To assess the rate and type of retinal break formation in patients undergoing 23 gauge transconjunctival vitrectomy surgery for complications of proliferative diabetic retinopathy compared with 20 gauge vitrectomy surgery. METHODS Retrospective case notes review of two consecutive series of patients who had primary pars plana vitrectomy for(More)
INTRODUCTION Patient compliance is essential to ensure efficacious treatment. The ease of topical drop delivery is of paramount importance. At least 50% of patients report difficulty in self-administration of topical ocular medicine. The two most frequently reported causes of difficulty include aiming the bottle and squeezing the bottle. PURPOSE The aims(More)
PURPOSE Prescription and drug errors are common causes of adverse clinical events, posing a significant risk to safe patient care. Although there has been a movement to increase the use of electronic prescribing, concerns over feasibility suggest that improving the design of written prescriptions to minimize missing information may still be worthwhile. This(More)
Chemical burns of the eye represent 7.0%-9.9% of all ocular trauma. Initial management of ocular chemical injuries is irrigation of the eye and conjunctival sac until neutralisation of the tear surface pH is achieved.We present a case of alkali injury in which the raised tear film pH seemed to be unresponsive to irrigation treatment. Suspicion was raised(More)
  • Robert Roos—senior Projects, Alan Connor, +10 authors David J
  • 2015
Since 1996 I have been the project director (or, in several cases, co-director) of sixty-six senior projects. I have also served as a reader on an additional fifty-five senior projects. Of the projects I have supervised, seven have won the Allegheny College Student Chapter of the Association for Melanie Neff's project (co-supervised with Mike Keeley) won(More)
Intravitreal bevacizumab is an increasingly common treatment choice for posterior retinopathy of prematurity. Despite concern about its systemic effects, there have been few studies on the lowest effective dose. The authors describe a case that was successfully treated with 0.16 mg of bevacizumab, the first time this dose has been reported.